Dataset opportunity
Elevationspine — 医疗影像数据集机会
Elevationspine 持有的中等规模医疗影像数据集，可用于诊断人工智能和计算机视觉。
Score
47.5
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球医疗诊断人工智能市场 = 2023 年为 11 亿美元，复合年增长率为 25.2%。
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-08-11
Elevation Spine lands FDA clearance for expandable interbody fusion system
medicaldevice-network.com ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
医疗影像数据集
Modality
图像
Sector
医疗保健
Volume
中等
Freshness
定期
Rarity
高（专有）
Accessibility
受限
Legal
混合所有权 — GDPR 敏感（个人身份信息审查）
Buyer persona
医疗人工智能与诊断影像公司
Elevationspine 持有源自其在脊柱医疗保健领域工作的专业医疗影像数据集。该数据集独特地结合了专有的临床前生物力学数据（`industrial_data`）和来自临床注册的真实世界证据（`medical_records`），提供了脊柱状况的全面视图，适用于训练和验证诊断人工智能算法。
该数据定位于快速增长的医疗诊断人工智能市场，该市场在 2023 年的估值为11 亿美元，预计将以 25.2% 的复合年增长率扩张。[7] 尽管访问复杂性要求 HIPAA/GDPR 合规性以处理患者信息，并需要对其专有生物力学数据进行特定的知识产权许可，但该证据的稀缺性和监管级别性质使其成为开发下一代诊断工具的宝贵资产，该市场需求旺盛。⚠ 尽职调查（有价值的数据，可协商的访问权限）：临床注册数据包含受保护健康信息 (PHI)，需要 HIPAA/GDPR 合规性；临床前生物力学数据是专有的且“存档”，需要特定的知识产权许可；对真实世界证据 (RWE) 的访问取决于外科医生合作伙伴协议。· 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明 Elevationspine 拥有一个专有的临床注册，包含约 200 名患者的医学影像，直接与其FDA 批准的 Saber-C 颈椎融合器相关。这个稀有度高、真实世界的数据库是医疗人工智能公司用于训练或验证脊柱影像诊断人工智能的首选资产。在全球诊断人工智能市场预计每年增长超过 25% 的情况下，获得此类临床相关的骨科数据可提供独特的竞争优势。
See dimension details ↓- Dataset Specificity90
占主导地位的“medical_records”，医疗保健行业，3 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 条证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
定期
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
适用于诊断人工智能
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
由于医疗诊断人工智能市场的快速扩张（复合年增长率为 25.2%），买家需求异常高，这造成了对专业、高质量影像数据的迫切需求。[7]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
个人身份信息/受监管
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
中等难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 种证据类型，3 条命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License28
所有权=混合，许可=GDPR 敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation73
3 个数据需求信号（3 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高，1 个近期外部信号 — 专有数据超出已货币化的部分
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit58
⚠ 审查 — 该公司的核心业务是开发和销售医疗设备（脊柱植入物），而不是提供作为副产品生成数据的服务，因此不适合。问题：该公司的核心产品是物理医疗设备（脊柱融合植入物），它进行销售。[1, 2, 7]；该公司没有像 ICP 那样作为副产品生成数据的真实运营业务（例如，车队、检查、市场）。I；提及来自植入物的“数据点”是指用于产品改进的外科医生反馈，而不是来自手术的专有结构化数据集。
- Deep Qualification80
✓ 通过 — Elevationspine 是一家医疗设备制造商，使其成为一个`工具供应商`。临床和影像数据由其客户（外科医生/医院）生成和拥有，而不是公司本身。虽然该公司确实拥有专有的临床前数据并正在建立临床注册，但访问和转售有价值的真实世界影像数据的权利并非固有，并且取决于与医疗保健提供者达成的特定、未经证实的协议。
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
该公司正在建立一个临床注册，估计有 200 名患者，提供结构化的真实世界医学影像集合，对于训练诊断人工智能进行术后结果分析非常有价值。
Industrial data
该公司存档有未发布的临床前数据，提供了关于设备材料性能和生物相互作用的深入技术背景，可以丰富相关图像的解释。
Regulatory records
官方文件证实了公司设备的FDA 批准，这验证了临床流程并确保相关的患者数据是在严格的监管标准下生成的。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Elevationspine Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Diagnostics Market = $1.1 Billion in 2023, CAGR 25.2% (source: Market.us). [7]. Investment score 47.5/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Motusnova — 传感器遥测数据集机会
View opportunity →医疗保健Moonsurgical — 传感器遥测数据集机会
View opportunity →移动出行Green On — 移动遥测数据集机会
View opportunity →